Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Living Donors
Trial Timeline
Nov 1, 2005 → Dec 1, 2008
NCT ID
NCT01046955About Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab is a approved stage product being developed by Roche for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01046955. Target conditions include End-Stage Renal Disease, Living Donors.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01046955 | Approved | Completed |
Competing Products
20 competing products in End-Stage Renal Disease